Eledon Pharmaceuticals (ELDN) Return on Capital Employed (2014 - 2026)
Eledon Pharmaceuticals posted quarterly Return on Capital Employed of 57.45% for Q1 2026, down 4833.0% year-on-year from 1.21% in Q1 2025, and down 202.28% on a QoQ basis from 19.01% in Q3 2025.
Eledon Pharmaceuticals (ELDN) has 13 years of Return on Capital Employed data on file, last reported at 57.45% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 4833.0% year-over-year to 57.45%; the trailing twelve-month figure through Mar 2026 stood at 57.45% (down 4833.0% YoY), and the FY2025 full-year result was 29.43%, down 2326.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 57.45%, down from 19.01% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 5.27% in Q1 2022 and bottomed at 57.45% in Q1 2026.
- The 5-year median for Return on Capital Employed is 20.36% (2023), against an average of 21.0%.
- The widest annual swing landed in 2024, when Return on Capital Employed jumped 2201 bps; it then tumbled 4833 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 16.1% in 2022, then sank by 71 bps to 27.6% in 2023, then jumped by 80 bps to 5.59% in 2024, then sank by 240 bps to 19.01% in 2025, then slumped by 202 bps to 57.45% in 2026.
- The last three Return on Capital Employed figures came in at 57.45% (Q1 2026), 19.01% (Q3 2025), and 17.82% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | -57.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.45% |
| Sep 30, 2025 | -19.01% |
| Jun 30, 2025 | -17.82% |
| Mar 31, 2025 | -9.12% |
| Dec 31, 2024 | -5.59% |
| Sep 30, 2024 | -35.88% |
| Jun 30, 2024 | -29.99% |
| Mar 31, 2024 | -30.03% |
| Dec 31, 2023 | -27.60% |
| Sep 30, 2023 | -21.71% |
| Jun 30, 2023 | -23.20% |
| Mar 31, 2023 | -24.03% |
| Dec 31, 2022 | -16.10% |
| Sep 30, 2022 | -6.85% |
| Jun 30, 2022 | -6.40% |
| Mar 31, 2022 | -5.27% |
| Dec 31, 2021 | -4.57% |
| Sep 30, 2021 | -19.15% |
| Jun 30, 2021 | -15.90% |
| Mar 31, 2021 | -12.66% |
| Dec 31, 2020 | -9.60% |
| Sep 30, 2020 | -17.07% |
| Jun 30, 2020 | -118.55% |
| Mar 31, 2020 | -139.31% |
| Dec 31, 2019 | -136.58% |
| Sep 30, 2019 | -109.33% |
| Jun 30, 2019 | -122.72% |
| Mar 31, 2019 | -134.53% |
| Dec 31, 2018 | -88.19% |
| Sep 30, 2017 | -65.31% |
| Jun 30, 2017 | -57.94% |
| Mar 31, 2017 | -69.35% |
| Dec 31, 2016 | -118.12% |
| Sep 30, 2016 | -70.82% |
| Jun 30, 2016 | -79.59% |
| Mar 31, 2016 | -76.66% |
| Dec 31, 2015 | -67.93% |
| Sep 30, 2015 | -52.63% |
| Jun 30, 2015 | -40.02% |
| Mar 31, 2015 | -33.05% |
| Dec 31, 2014 | -22.75% |